Advancing Preclinical Predictivity

At MIMETAS, we disrupt the approach to preclinical research. Our human organ models empower pharmaceutical researchers in the fields of toxicology and ADME, enabling expedited safety and efficacy assessments of compounds.

3D Tissue Models for Precise Preclinical Toxicology

Unlocking the secrets of human physiology has long been a challenge in toxicity studies. However, our revolutionary technology now provides a breakthrough solution. By harnessing advanced human tissue and disease models with diverse quantitative assessments, researchers can delve into drug-induced toxicity with unparalleled relevance to human physiology for efficient risk management strategy. Unmanageable toxicity accounts for 30% of clinical drug development failures, primarily attributed to the limitation of traditional models in accurately reflecting human physiology.

Revolutionizing Toxicology

Get Inspired

Researchers from the Swiss Institute of Allergy and Asthma Research (SIAF) recently used the OrganoReady^® Colon Caco-2 and OrganoReady^®Colon Organoid to assess the impact of common household dishwashing detergents and rinse aids as well as food emulsifiers on potential harmful effects of these compounds on gastrointestinal health.

Food emulsifier paper

Dishwashing detergent paper

Investigative Toxicology

Our models recreate the intricate cellular interactions of human organs, enabling researchers to unravel the mechanisms behind adverse effects, study dose-response relationships, and gain deeper insights into complex toxicological pathways.

Predictive Toxicology

We offer the unprecedented opportunity to forecast potential toxicity outcomes, aiding in early-stage compound screening, reducing animal testing, and expediting regulatory approval

Comprehensive ADME and PK/PD Insights

Our advanced 3D models redefine ADME (Absorption, Distribution, Metabolism, and Excretion) research by replicating intricate organ interactions with unprecedented human relevance. With unparalleled precision, we unravel a drug's journey within the body, offering insights into:

Bioavailability
Tissue accumulation
Metabolic stability
Potential pharmacokinetic and pharmacodynamic interactions

Harnessing these dynamic insights allows for informed decisions in drug development, optimized dosing regimens, and an accelerated pipeline to safer, more effective pharmaceutical solutions.

Get inspired

A 3D Human Blood-Brain Barrier Model to Study Small Molecule Transport

Our blood-brain barrier (BBB) model offers a complex system for small molecule transport assessment. Displaying phyiologically relevant junction and transporter expression profiles, our BBB model enables the study of barrier function and antibody transcytosis in high-throughput.

Read the case study

Explore some of our Organ Models:

Colon Organoid and Colon Caco-2 Models
Assess drug absorption and metabolism in the gastrointestinal tract, vital for evaluating gut-related toxicity and drug interactions.
Blood-Brain Barrier Model
Investigate drug transport across the blood-brain barrier, enabling strategic targeting of neurotherapeutics and minimizing CNS-related risks.
Kidney Model
Investigate nephrotoxic compounds' impact on human renal tissue, unlocking insights into kidney diseases and drug-induced nephrotoxicity.
Blood Vessel Model
Study drug distribution and vascular effects for improved pharmacokinetic evaluations, facilitating targeted drug delivery to specific tissues.

The OrganoReady® models

A colon organoid tubular structure with cellular polarization with an immunofluorescence staining of the tight junction Occludin (green) and cell nuclei (blue). This model is available with OrganoReady Colon Organoid.

Commitment to Ethical Excellence

At MIMETAS, ethics and innovation go hand in hand. We are proud to contribute to the replacement, reduction, and refinement of animal use in research. By providing an alternative to animal models, we enable safer, more effective, and ethical research that translates to human biology. Our approach aligns seamlessly with the championing innovation while prioritizing patient safety and sustainable practices.

Pioneering Organ-on-a-Chip Expertise

Embrace the Future of Drug Development with MIMETAS - Collaborate with us today to redefine pharmaceutical possibilities, drive meaningful progress, and enhance patient care through our advanced organ-on-a-chip technology. Together, we can shape a brighter, more sustainable future for healthcare worldwide.

If you are interested in exploring potential partnership opportunities or learning more about our ongoing projects, please contact us.

Contact us